Living Forever retweeted
Cancer billing codes cover surgery, chemo, radiation and immunotherapy given through the whole body. No code covers going into the tumor to get the immune system to do the heavy lifting.
@drgoodyear points out that doctors and hospitals don't do it because they can't bill for it, even where it may work better for the patient. I agree with him that the coding system protects itself before it protects patients.
Living Forever retweeted
The best way to get the general population to trust AI is to solve the problems that affect them daily. Prices, diseases, the environment, etc.
The opportunities for the industry are endless.
Let's hope a cure for all diseases and aging follows a similar timeline.
Demis Hassabis predicted it will take 2 years until AI solves the Riemann hypothesis or another Millennium Prize problem.
6 months later, we’re looking at proposed solutions to BOTH Riemann and Navier–Stokes.
what a time to be alive!
22
Not just factories but nursing homes, hospitals, and in home caregivers. Although hopefully science will soon solved medical issues to the point where people no longer need such assistance.
BREAKING: Humanoid robots are entering the world of heavy-duty industrial labor. Foundation Robotics has just launched Phantom MKII, a new humanoid designed to lift up to 200 pounds and work across factories, construction sites, mining operations, and potentially in warfare.
The 6-foot-tall humanoid weighs 195 pounds, with a 4–6-hour runtime and 29 degrees of freedom. It's designed to withstand harsh environments, including rain, snow, dust, and heat.
Living Forever retweeted
I am still shocked as to how little of medical progress is reported. And in the meantime, people are dying not knowing that maybe there is a cure or at least a possibility of cure somewhere in the world. It is amazing that politics and celebrities still fill the media.
Living Forever retweeted
Five people with stage 4 pancreatic cancer now have no cancer showing on their scans.
All 61 patients in this trial came in untreated and got daraxonrasib plus chemo as their first treatment. Tumors shrank in 6 out of 10 of them. Chemo by itself usually holds this cancer back for about 5 or 6 months. With daraxonrasib added, the median was close to 13.
These patients had not been worn down by rounds of chemo yet, so their immune systems were still intact. I think intact immune systems are a big part of why the responses ran so deep.
The drug is great. Delivery is still the problem. Swallowing a pill sends the drug through the whole body. We inject these drugs right into the tumor, so the cancer takes the hit and the immune system stays strong.
Now we need to turn remissions into cures, and the immune system is how we get there.
Protect this man and invest in his company!
Dario Amodei: My father died of a disease that became curable a few years later
"Daniela and I lost our father to a disease that, just a few years later, became curable."
"I started my career in biology hoping to help future cures come sooner."
"We hope that in the future, fewer families miss a cure by a few years."
1
25
Invest in Anthropic. You'll help save lives - maybe your own!!!
Anthropic’s IPO could help fund the next wave of companies that change your life. Thousands of newly wealthy employees can now back the next generation of founders in AI, robotics, and biotech...
I joined @CNBC and explained why I think the pace of change is about to get even faster, and why society is still underestimating what’s coming.
23
Everyone should be investing in this company!!!
Dario Amodei reveals Anthropic discovered what looks like a new gene-editing mechanism and says it may discover dozens a month within months
“I’ve been talking to our biology team several times a week. We discovered what looks like a new gene editing mechanism, and I think within a few months we may be discovering dozens of them every month. We’ve seen, with the speed at which this technology moves, these little sparks will soon turn into a firestorm.”
“I think that we can find a way to build this technology safely, in a way that benefits people, that addresses all the risks, and that delivers a world that is so much better than the world we have today. We haven’t done that yet. We haven’t earned the right to talk about how great those things are, but we’re starting down the path.”
33
Living Forever retweeted
scientists just started testing a drug on real humans that regrows your teeth
no implants, no dentures, your body just grows a real one back
it works because you may already have a spare set of tooth buds hiding in your jaw
> they never grow because a protein called USAG-1 keeps switching them off
> this drug blocks that protein, so the buds can turn into real teeth
> in mice, one dose was enough to grow a whole new tooth
> adults in Japan already got the drug in the first human trial, and so far it looks safe
next it'll be tested on 24 kids born missing teeth, with the goal of hitting the market by 2030
and if it works for them, the long-term plan is anyone who's lost a tooth
the future of dentistry might just be a drip and some patience lol
Living Forever retweeted
Dario Amodei shared that he and his sister and co-founder Daniela lost their father to an illness that became curable only a few years after his death.
That loss pushed him into biology and still drives his belief that AI can bring cures sooner.
- Dario was speaking in front of the Nasdaq ahead of the day's Opening Bell.
----
Full video on "CNBC Television" YouTube channel, (link in comment)
Living Forever retweeted
Transhumanism, at least certain elements of that philosophy (especially ones that center on radically extending healthy human lifespans) is about to get its day in the sun.
Remarks from Anthropic CEO @DarioAmodei on our initial public offering:
My co-founders and I started Anthropic because we believe that the most powerful technology of our time should be built for the benefit of humankind.
Daniela and I lost our father to a disease that, just a few years later, became curable. I started my career in biology, hoping to help future cures come sooner. In the lab, I saw the vast thicket of complexity that scientists face when they’re trying to understand disease and develop new treatments.
So many of the scientific tools that can cut through that thicket—tools for gene editing, gene synthesis, controlling brain cells with light—started as pure ideas. In other words, they came from thinking. From intelligence.
Human intelligence has already made diseases like plague, smallpox, and polio history for most of the world. But progress on other diseases has been too slow for so many patients and their families. Going from a great idea to a treatment can take decades: it took many years from the first discovery of a strange repeating pattern in DNA to the approval of the first treatment for a disease using CRISPR.
Nature is full of these patterns. But we’ve had too little intelligence to decipher most of them; too few scientists, with too little time. Now we can build that intelligence. Whether it’s protein folding, drug design, cancer genetics, or clinical trial administration, scientists across many areas of biology and medicine are finding Claude can help them do their research in a fraction of the time it would’ve taken just a couple of years ago. I believe sufficiently powerful AI, working in concert with humans, could compress a century of scientific and medical progress into a decade.
I don’t want to get ahead of myself. At this point all we have are early results. Experiments and clinical trials will still take time. And although they involve slow and ponderous processes, I believe those processes can be substantially accelerated by AI. We hope that in the future fewer families miss a cure by just a few years.
Medicine is just a particularly vivid example, but there are many others. Our customers—the world’s most ambitious companies, nonprofits, and individual people—are already applying the intelligence we’ve built to stimulate economic growth; lift people out of poverty; protect democracy and free societies; even make everyday services like the DMV work better. We’re proud to work alongside them. And I’m extremely optimistic about what we can do together in the future.
At the same time, we have always been honest that this technology has very real risks. These range from misuse of the technology by individuals or nation-states, to economic disruption, to losing control of AI systems. We discuss these risks not because we think they are inevitable, but because we think they are avoidable.
Avoiding them depends on the choices made by the people building AI. There is a gigantic difference between how AI will go if we pay little attention to safety, versus how it will go if we are obsessed with safety. And an obsession with safety and with public benefit has been woven into Anthropic’s DNA from the start. From safeguards against biological and cyber risks, to alignment training and testing, to looking inside our models like an X-ray, Anthropic has pioneered methods for understanding and steering the behavior of AI systems.
There is much work still to be done, and the most difficult safety work lies ahead of us. The incredible talent of the company that has enabled us to build the most capable AI systems will need to be directed, even more so than it has already, towards double- and triple-checking that those AI systems are safe and secure.
And to state it unequivocally, we will pace the training and deployment of AI systems, taking as long as is necessary to have confidence that they are safe and will remain under human control. We will not bend to either business or political pressure. Today puts the company in a stronger financial position, and in doing so only strengthens our resolve to do the right thing.
If we can show it’s possible to make the right choices on safety and still build an incredibly successful company, others in our industry will be inspired to do the same. We call this a race to the top. When the race to the top is working properly, it doesn’t matter which company has the best models—everyone wins because everyone is building safely. The race to the top works best when driven from the front of the pack, and we fully hope and expect to do so, but the goal is to make the whole industry better, regardless of whether Anthropic is winning or losing at any given time.
The advent of machine intelligence is one of the seminal moments in human history, and we have a rare opportunity to shape it for the better.
This moment is bigger than any one company, or any one country. It will take all of us, working together, to ensure this technology goes well for us and the many generations to come. Starting today, we hope that you’ll join us on this mission.
Living Forever retweeted
Congrats to Anthropic & all their amazing scientists! $2T market cap. A new age of medicine begins! 🧬🚀
Living Forever retweeted
Anthropic CEO Dario Amodei’s IPO-day speech at Nasdaq’s opening bell
“I believe sufficiently powerful AI, working in concert with humans, could compress a century of scientific and medical progress into a decade.”
“We will not bend to either business nor political pressure.”
Living Forever retweeted
Elon Musk says Neuralink’s next product, Blindsight, will enable people who are completely blind to see:
“Our next product is what we call Blindsight.”
“Blindsight is a neural implant that interfaces directly with the visual cortex and enables people who are completely blind to see.”
“You’re wearing glasses or something like that that have a camera. That camera is transmitting to the Neuralink device that then transfers the signals to your visual cortex.”
“Enabling someone who is completely blind, meaning blind in both eyes or lost the optic nerve, potentially someone who has been blind from birth, to see.”






















